Posts Tagged ‘Events’

I want to believe…

Comments Off
Posted 02 Dec 2011 — by Sophie Beauvais
Category News

… that “an AIDS-free generation is possible.” Armed with growing evidence supporting pre-exposure prophylaxis (PrEP), a.k.a. “treatment as prevention”, President Obama yesterday made this statement and pledged increased support along the way, setting a new target of helping 6 million people get treatment by the end of 2013, upping the current number by 2 million.

Raising awareness and hope for HIV/AIDS in Uganda

There is good reason to believe. On December 1, world leaders and organizations marked World AIDS Day, which was themed “Getting to Zero” (in-line with the UNAIDS strategy). Thirty years into the epidemic, over 65 million people have been infected with the human immunodeficiency virus (HIV), over 30 million have died, and there are currently 34 million people living with HIV/AIDS worldwide as Jennifer Weinberg recaps in the Global Pulse Journal Blog. Among major milestones, the overall continued decrease in rate of new infections, deaths, and ART cost are paramount (see the UNAIDS World AIDS Day Report 2011 for more details – PDF).

Read More

Know your epidemiology: one lesson of many for GeneXpert roll-out

Comments Off
Posted 17 May 2011 — by Sophie Beauvais
Category News

A GeneXpert IV unit for MTB applications inside the FIND/WHO program © Cepheid

One week into the GeneXpert online panel, discussion is highlighting the critical importance of understanding the local epidemiology for tuberculosis (TB), especially for multidrug-resistant TB (MDR-TB) and also for HIV-associated TB. Prioritizing these two risk groups in diagnostic algorithms that use the Xpert MTB/ RIF as the initial diagnostic test is a key message for the efficient integration of this new tool into existing health systems. But it is by no means the only key message.

For years health implementers in high endemic areas with limited resources have been struggling with the lack of a rapid and reliable diagnostic test for HIV-associated TB and MDR-TB. Hence, the endorsement of the fully-automated nucleic acid amplification test (NAAT) by the WHO in December 2010 has been welcomed with enthusiasm from both implementers and donors. This novel tool reliably detects TB DNA in sputum specimens in less than two hours with 94.4 percent sensitivity for the simultaneous detection of rifampicin resistance with 98.3 percent specificity. Along with the WHO endorsement, many questions have arisen as to how best integrate this technology along with existing TB diagnostic tools in countries, especially those most affected by the disease and with limited resources.

Read More